

**Milestone Pharmaceuticals Inc.
1111 Dr. Frederik-Philips Boulevard, Suite 402
Montréal, Québec CA H4M 2X6**

VIA EDGAR

November 4, 2021

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Attn: Christopher Edwards

Re: **Milestone Pharmaceuticals Inc.
Registration Statement on Form S-3, as amended
File No. 333-257404**

Acceleration Request

**Requested Date: Friday, November 5, 2021
Requested Time: 4:00 P.M. Eastern Time**

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the "**Registrant**") hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-257404) (as amended to date, the "**Registration Statement**") to become effective on Friday, November 5, 2021, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.

The Registrant hereby authorizes each of Marc Recht, Ryan Sansom and Eric Popp of Cooley LLP to make such request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Eric Popp of Cooley LLP, counsel to the undersigned registrant, at (617) 937-2369.

[Signature Page Follows]

Sincerely,

Milestone Pharmaceuticals Inc.

By: /s/ Joseph Oliveto

Joseph Oliveto

Chief Executive Officer

cc: Amit Hasija, Milestone Pharmaceuticals Inc.

Ryan Sansom, Cooley LLP

Eric Popp, Cooley LLP
